Humacyte Files 8-K: Regulation FD Disclosure & Other Events
Ticker: HUMAW · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1818382
| Field | Detail |
|---|---|
| Company | Humacyte, Inc. (HUMAW) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, corporate-events
TL;DR
Humacyte filed an 8-K on 12/19/24 covering Reg FD disclosures and other events.
AI Summary
On December 19, 2024, Humacyte, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. Humacyte, Inc. was formerly known as Alpha Healthcare Acquisition Corp. until a name change on July 16, 2020.
Why It Matters
This 8-K filing provides important updates and disclosures for Humacyte, Inc., which could impact investor understanding of the company's current status and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.
Key Players & Entities
- Humacyte, Inc. (company) — Registrant
- Alpha Healthcare Acquisition Corp. (company) — Former company name
- December 19, 2024 (date) — Date of earliest event reported
- July 16, 2020 (date) — Date of name change
FAQ
What specific events are disclosed under Regulation FD in this 8-K filing?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.
What other events are reported in this 8-K filing?
The filing mentions 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.
When did Humacyte, Inc. change its name from Alpha Healthcare Acquisition Corp.?
Humacyte, Inc. changed its name from Alpha Healthcare Acquisition Corp. on July 16, 2020.
What is the principal executive office address for Humacyte, Inc.?
The principal executive office address for Humacyte, Inc. is 2525 East North Carolina Highway 54, Durham, NC 27713.
What is the SEC file number for Humacyte, Inc.?
The SEC file number for Humacyte, Inc. is 001-39532.
Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-12-20 16:25:37
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share HUMA The Nasdaq Stock Market
- $11.50 — of Common Stock at an exercise price of $11.50 HUMAW The Nasdaq Stock Market LLC Ind
Filing Documents
- huma-20241219.htm (8-K) — 31KB
- huma-20241219xexx991.htm (EX-99.1) — 28KB
- image_0a.jpg (GRAPHIC) — 21KB
- 0001818382-24-000227.txt ( ) — 262KB
- huma-20241219.xsd (EX-101.SCH) — 2KB
- huma-20241219_def.xml (EX-101.DEF) — 16KB
- huma-20241219_lab.xml (EX-101.LAB) — 27KB
- huma-20241219_pre.xml (EX-101.PRE) — 16KB
- huma-20241219_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 19, 2024, Humacyte, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has granted a full approval for SYMVESS (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On December 19, 2024, the Company announced that the FDA has granted a full approval for SYMVESS for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release, dated December 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HUMACYTE, INC. Date: December 20, 2024 By: /s/ Dale A. Sander Name: Dale A. Sander Title: Chief Financial Officer, Chief Corporate Development Officer and Treasurer 2